Connection between circadian rhythms and neurodegenerative diseases by Leng, Yue et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Manuscript version: Author’s Accepted Manuscript 
The version presented in WRAP is the author’s accepted manuscript and may differ from the 
published version or Version of Record. 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/111369                             
 
How to cite: 
Please refer to published version for the most recent bibliographic citation information.  
If a published version is known of, the repository item page linked to above, will contain 
details on accessing it. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions. 
 
© 2018 Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-
NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/. 
 
 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk. 
 
1 
 
Connection between circadian rhythms and neurodegenerative diseases 
Yue Leng, PhD1 2*, Erik S. Musiek, MD, PhD3, Kun Hu, PhD4 5, Francesco P. Cappuccio, MD, FRCP6 
Kristine Yaffe, MD7 
1. Department of Psychiatry, University of California, San Francisco, 4150 Clement Street, San 
Francisco VA Medical Center, CA 94121, USA 
2. Shanghai Jiao Tong University School of Medicine, 280 South Chongqing Road, Shanghai, China 
3. Department of Neurology, Hope Center for Neurological Disorders, and Knight Alzheimer Disease 
Research Center, Washington University School of Medicine, St. Louis, MO 63110, USA 
4. Medical Biodynamcis Program, Division of Sleep and Circadian Disorders, Departments of 
Medicine and Neurology, Brigham and Women’s Hospital, Boston, MA 02115, USA 
5. Division of Sleep Medicine, Department of Medicine, Harvard Medical School, Boston, MA 02115, 
USA 
6. Division of Health Sciences (Mental Health and Wellbeing), Warwick Medical School, University of 
Warwick, Coventry CV4 7AL, UK. 
7. Departments of Psychiatry, Neurology, and Epidemiology, University of California, San Francisco, 
San Francisco VA Medical Center, San Francisco, CA 94121, USA. 
 
* Corresponding author: 4150 Clement Street, San Francisco VA Medical Center, San Francisco, CA. 
Email: yue.leng@ucsf.edu. Tel: 415-221-4810 
 
  
2 
 
 
I. Abstract 
Increasingly circadian rhythms have been linked to age-related diseases. We provide an up-to-
date review (2013-2018) of the association between circadian rhythm disruptions (CRD) and the 
most common types of neurodegenerative diseases, including Alzheimer’s disease and related 
dementias (ADRD) and Parkinson’s disease (PD). CRD differ according to type and severity of 
neurodegenerative diseases, and importantly, could occur early during the course of 
neurodegeneration as a prodrome. Evolving evidence also supports CRD as a potential risk factor 
for developing ADRD and PD, although confirmatory studies are needed. Proposed mechanistic 
pathways underlying this association include alterations in sleep, protein homeostasis, and 
immune and inflammatory function. While promising, more studies of CRD and treatment trials 
are needed to determine whether circadian interventions may prevent or delay the onset of 
neurodegenerative diseases. The study of circadian rhythms holds great promise for a role in the 
prevention and management of neurodegenerative diseases.         
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Panel 1.  
Glossary Panel 
Amplitude: Magnitude of a cycle, or the difference between peak and trough values. In relation to a 
hormonal cycle, for example, it would be the difference in the levels of the hormone from the trough 
to the peak within a time period (i.e. 24 hours). 
Circadian rhythm: An approximately 24-hour cycle in the physiological processes of most 
organisms, endogenously generated, and modulated by external cues. 
Circadian rhythm sleep-wake disorders: Disorders related to the timing of sleep and wakefulness 
that are characterized by the inability to fall asleep, remain asleep, and/or wake at the desired time. 
Circadian misalignment: A loss of synchrony between internal circadian rhythms, behaviors and 
the external environment, as a result of a variety of circumstances (e.g. jet lag, shift work). 
Entrainment: The resetting of circadian cycle to maintain synchrony with daily environmental and 
behavioral cycle. 
Irregular sleep-wake rhythm disorder: A lack of clear 24-hour sleep-wake pattern, usually with 
long periods of wakefulness during the night and irregular bouts of sleep throughout the day; most 
common in patients with neurodegenerative diseases. 
Mesor: The mean value around which the rhythm oscillates. 
Period: Time interval between two reference points within a rhythm or recurring wave. 
Phase: Timing of a reference point in the cycle relative to a fixed event. In relation to a sleep-wake 
cycle, for example, a phase advance (delay) would mean that sleep timing moves earlier (later). 
Sundowning: Increasing behavioral and neuropsychiatric symptoms around the time of sunset, 
commonly seen in dementia patients. 
Zeitgeber: an external or environmental cue (e.g. light, temperature) that synchronizes an 
organism’s internal biological rhythms to the external 24-hour light-dark cycle. 
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II. Introduction  
The award of the 2017 Nobel Prize in Physiology or Medicine to Hall, Rosbash, and Young for 
their work on the molecular mechanisms of the circadian clock highlights the importance of 
circadian rhythms and their relation to health and wellbeing (1). In humans, circadian rhythm 
activities change markedly as people age, and these changes might further accelerate the aging 
process (2). While it is recognized that circadian dysfunction in older adults can be partly 
attributed to the degeneration of the suprachiasmatic nucleus (SCN), known as the “master 
circadian clock” in mammals, the link between circadian rhythms and neurodegeneration is not 
fully understood. Patients with neurodegenerative diseases frequently experience circadian 
rhythm disruptions (CRD) (3-5). For example, they become more active during the night, less 
active during the day, and sometimes have complete reversal or loss of the 24-h rest-activity 
pattern (6, 7). Importantly, growing evidence suggests that disruptions of circadian functions 
could be early manifestations of neurodegeneration, and might even be a risk factor to the 
development of neurodegenerative diseases in healthy older adults (8-10). Greater understanding 
of the relationship between circadian rhythms and neurodegeneration could be key to the early 
identification and management of neurodegenerative diseases. 
This review discusses the association between circadian rhythms and neurodegenerative diseases 
by summarizing evidence from both human and animal studies. In order to provide a most up-to-
date review of the evidence, we mainly discuss the empirical findings published within the past 5 
years, except for certain landmark studies. We referred to a few previous reviews (11-13) for 
detailed discussion of earlier studies.  This review focuses on Alzheimer’s disease and related 
dementias (ADRD) and Parkinson’s disease (PD), as these are the most common 
neurodegenerative diseases and have been studied most in relation to circadian rhythms. We 
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introduce key concepts related to circadian rhythms (See Glossary Panel), present both 
behavioral and biological circadian features in patients with ADRD and PD, summarize findings 
from clinical and longitudinal epidemiologic studies regarding the effects of CRD on the 
development of ADRD and PD, and discuss underlying mechanisms. Finally, we describe the 
results of different circadian interventions, especially in those with ADRD and PD, and discuss 
future directions.      
 III. Circadian rhythms  
A circadian rhythm (from the Latin ‘circa’ = about and ‘diem’ = a day) is an approximately 24-
hour cycle in the physiological processes of most organisms that is endogenously generated and 
can be modulated by external cues (14). A circadian cycle is characterized by several features. It 
is self-sustained, as the rhythm persists in the absence of any exogenous time signals 
(Zeitgebers), including dark-light cycles. This characteristic indicates the presence of an intrinsic 
time-keeping mechanism (i.e. biological clock). It shows rhythmicity, as they persist with a cycle 
of approximately 24 hours. It also shows the ability to be synchronized by external cues, such as 
the dark-light cycle or other social and environmental modulators, like activity and temperature. 
The circadian rhythmicity is typically measured by three parameters: amplitude, phase and 
period.  Amplitude is defined as the magnitude of a cycle, or the difference between crest and 
trough values. In relation to a hormonal cycle, for example, it would be the difference in the 
levels of the hormone from the trough to the peak within a time period (i.e. 24 hours).  Phase 
(advanced or delayed) is defined as the timing of a reference point in the cycle relative to a fixed 
event. In relation to a sleep-wake cycle, for example, a phase advance (delay) would mean that 
sleep timing moves earlier (later). Period is the time interval between two reference points within 
a rhythm or recurring wave (for example between two hormonal peaks). 
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Circadian rhythms are generated in highly specialized cells of specific structures of the brain that 
control a complex network of coupled self-sustained clocks in the brain and in the peripheral 
organs. In mammals, the central or master clock of the circadian network is located in two 
groups of neurons called the SCN, in the anterior hypothalamus. The SCN consists of 
approximately 20,000 specialized neurons, which receive direct synaptic input from the retina, 
synchronizing activity to the external light- dark cycle (15). Light input serves to synchronize the 
core cellular clock machinery in SCN neurons, which keeps 24-hour time and in turn 
synchronize cellular clocks throughout the body via neurohormonal modulation. At the 
molecular level, the properties of circadian clocks are based on changes in the expression of 
certain genes and consist of proteins which form a transcriptional-translation feedback loop that 
is tuned to a 24-hour period (16).  The clock proteins BMAL1 and Clock interact to drive 
transcription of clock-controlled genes, including their own negative feedback repressors, which 
include PERIOD, CRYTOCHROME, and REV-ERB proteins (17).  This transcriptional 
feedback loop maintains 24-hour rhythms in gene expression which are required for behavioral 
and physiologic rhythmicity at the organismal level.  While light is the primary circadian cue, 
resetting the circadian cycle in synchrony with the daily environmental and behavioral cycle 
(entrainment) is achieved through the 24-h cycle of light input (photic synchronizer) to the SCN 
and neurohormonal modulations (non-photic synchronizers) (e.g. temperature, food availability, 
social interactions) for the peripheral ones.  Importantly, in the absence of external cues, such as 
in constant darkness, the circadian system retains a near 24-hour rhythm, while light cues that are 
out of phase with the SCN cause a gradual resetting of the clock to entrain to the new rhythm.  
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The pattern of one’s circadian rhythm can be measured with both biological and behavioral 
markers. Landmark experiments by Czeisler et al. (18) identified core body temperature (CBT), 
as well as melatonin and cortisol secretions, as ‘circadian’ biomarkers, oscillations of which are 
controlled by the SCN. In normally entrained individuals, CBT has a rhythm that falls during the 
night and rises in the early hours of the morning; cortisol peaks in blood and saliva early in the 
morning, then regularly decreases throughout late morning and afternoon, to reach low values 
during evening and night, thereby availing sleep; melatonin is generated by the pineal gland, 
with its onset near sunset, peak during the nighttime hours and offset after sun rise, thereby 
stimulating wakefulness. The circadian rhythm of melatonin in saliva or plasma is one of the 
most commonly used circadian phase biomarkers in human beings (19).  The onset time of 
melatonin secretion under dim light conditions, known as the dim light melatonin onset 
(DLMO), has been suggested as the single most accurate circadian phase marker in humans (20).   
Behavioral markers of circadian rhythm mainly include sleep-wake cycles and rest-activity 
rhythms.  The circadian system has powerful influence over the sleep-wake cycle, such that it is 
often difficult to distinguish the relative contributions of the two sleep regulatory systems (the 
sleep-wake homeostasis and the circadian timing system) to behavior. The circadian clock 
regulates the timing of sleep, as mutations in core circadian clock genes in mice and humans 
manifest as sleep phenotypes, including short sleep time, early or late sleep phase, or fragmented 
sleep-wake rhythms (21, 22). Moreover, clock gene expression can be influenced by sleep 
deprivation, emphasizing that these systems are interrelated. While specific circadian analyses 
can be used to parse out aspects of CRD from behavioral data, activity must be monitored around 
the clock for several days.  Some circadian biomarkers, such as the timing of melatonin secretion 
or oscillation of selected clock genes in blood, maintain their 24-hour oscillations even in the 
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face of sleep deprivation (23, 24).  Therefore, it is important for studies to include both 
behavioral and biological markers of circadian rhythms to more robustly identify CRD. Given 
the scope of this review, we include studies if they present information on biological markers or 
behavioral markers related to sleep timing, daytime sleep/sleepiness and rest-activity rhythm; 
studies that only present nocturnal sleep disruptions are excluded.    
Age-related changes in any of the structures or processes involved in generating or entraining 
circadian rhythms may modify circadian rhythmicity with advancing age. In particular, circadian 
phase has been shown to move earlier, or advance, with age (25), while the amplitude of the 
rhythms tend to decrease (26). For example, older adults have decreased peak melatonin, 
elevated nadir level of CBT, and a phase advance (earlier onset) in the peak of these rhythms (2) 
(27) (28). Age-related changes in sleep-wake cycles may be related to circadian dysfunction and 
include earlier bedtimes and rise times, increased sleep fragmentation, and increased daytime 
sleepiness that has been frequently suggested as an early indicator of declining health in the 
elderly (29, 30). Duffy et al. reported that older adults are more prone to several circadian 
rhythm sleep-wake disorders (CRSWDs), including advanced sleep wake phase disorders 
(ASWPD), jet lag disorder and shift-work disorder, due to an inability to fall asleep or remain 
asleep, conflicting with desired sleep timing (31, 32). The circadian system is paramount for 
optimal biological functioning, maintaining synchrony between internal physiology, behavior, 
and the cues deriving from the external environment. When this synchrony is lost, e.g. due to jet 
lag, shift work, or chronic sleep deprivation, a “circadian misalignment” occurs, leading to 
significant health consequences affecting cardiovascular, metabolic, cognitive, immunological 
and oncogenic processes, with impact also on safety, performance and productivity (33-35). 
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IV. Disruption in neurodegeneration 
a. Alzheimer disease and related dementias 
The prevalence of circadian disruption in patients with moderate-to-severe AD has been 
recognized for more than two decades (6). AD patients were often considered to have much more 
severe circadian disruptions compared to healthy older adults, including higher fragmentations, 
dampened amplitude and phase delay, as opposed to more typical advanced circadian phase 
associated with normal aging (6).  It was suggested that “sundowning”, known as the increasing 
behavioral and neuropsychiatric symptoms in AD patients around the time of sunset, could also 
partly be attributed to the phase delay of temperature and hormone rhythms in AD (36)(37). The 
most common CRSWD seen in AD patients is irregular sleep-wake rhythm disorder (ISWRD), 
as opposed to ASWRD in healthy older adults. ISWRD is defined as a lack of clear 24-hour 
sleep-wake pattern, usually with long periods of wakefulness during the night and irregular bouts 
of sleep throughout the day which might get worse in severe AD (38, 39). 
Over the past five years, a growing number of studies focused on patients of various levels of 
cognitive impairment and found their circadian patterns differed from those reported in previous 
studies (6). These studies (Table 1) included patients with pre-clinical AD (8), mild cognitive 
impairment (MCI) (40) (41), mild AD (3) (42) (43), moderate to severe AD (43), global AD(44), 
as well as early onset dementia (EOD) (4). All of these studies have reported on behavioral 
markers of CRD, including disruptions of rest-activity rhythms and sleep timing. Two studies (3, 
40) examined melatonin rhythms using saliva melatonin assay, one study (41) assessed 
temperature rhythms using a wrist temperature sensor, and one study (3) also examined 
peripheral clock gene expression. Overall, studies have found high rest-activity rhythm 
fragmentation(4) (8) but only a slight reduction or no change in the amplitude of rest-activity or 
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melatonin rhythms (3, 4, 8, 42, 44). One recent US study in 189 cognitive normal older adults 
(50 with preclinical AD pathology) showed decreased rhythm amplitude associated with aging, 
but not with AD pathology(8). Another study in 16 mild-moderate AD patients from Italy found 
large variability among individual actigraphic profiles, which could have also contributed to the 
overall minor changes in the amplitude of rhythms in these patients (42).  There are mixed 
findings with regard to changes in circadian phases. The Rush Memory and Aging Project 
suggested a significant phase delay in rest-activity rhythm among 7 AD patients compared to 10 
controls (44), whereas a study of 48 AD patients from Italy showed an advanced bedtime in AD, 
especially for moderate to severe cases of AD (43).  Meanwhile, two recent studies of MCI 
patients both found a phase advance, one in melatonin and sleep onset (40), and another in CBT 
and activity rhythm (41).    
In general, studies that focused on more severe AD found more circadian disruptions, while 
studies in MCI, preclinical AD and mild AD suggested moderate circadian changes (3) (8) (40).  
Weissova et al. found no correlation between circadian features and severity measures of AD in 
16 mild to moderate AD patients (42). No study to date has examined change in circadian 
rhythms with the progression of AD symptoms. Few studies have examined molecular 
perturbations in circadian clock oscillations in ADRD, though alteration in clock gene 
methylation and expression have been described in patient fibroblasts (45), and altered clock 
gene expression noted in post-mortem tissue (46). Further, evidence specifically pertaining to 
circadian disruptions among patients with non-AD dementia is sparse. Larger and longitudinal 
studies are needed to determine the correlation between both behavioral and biological markers 
of CRD and severity or progression of AD. Additional studies designed to establish circadian 
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markers and features specific to each type of dementia might help with the differential diagnosis 
of the disease. 
b. Parkinson’s disease 
Both motor and non-motor manifestations of PD show disruptions in their typical 24-h 
oscillations. Unlike patients with ADRD, CRD among PD patients is featured by a reduction in 
the amplitude of the circadian rhythm but no significant shift in circadian phases (5) (47) (48) 
(49) (50) (51). Sleep-wake disturbances as a whole are the most common non-motor symptom of 
PD patients, affecting up to 80% of PD patients (52). Indeed, five of the six studies (Table 2) that 
examined circadian features in PD patients reported on either excessive daytime sleepiness 
(EDS) (5) (47) (48) or sleep timing (48) (51) (49). It was reported that PD patients were at least 
twice as likely to experience EDS compared to healthy older adults (5, 47). Only one study 
reported slightly later sleep onset time in 30 PD patients compared to 15 healthy controls from 
England (53), while the others did not find significant differences in sleep timing (49, 51). One 
Australian study found among 12 PD patients a significant reduction in the mesor (mean value 
around which the rhythm oscillates) and amplitude of their CBT rhythm, compared to 11 healthy 
controls(49). Three studies examined rhythms of melatonin secretion, using plasma (5), serum 
(48) and saliva melatonin (51), respectively. While none of these studies found a difference in 
the timing of melatonin onset, most found significantly reduced circulating melatonin levels 
among PD patients (5) (48). Importantly, the usual circadian dip in blood pressure during the 
night may be lost in PD, putting patients at significantly higher risk for cardiovascular 
complications including nocturnal hypertension (50). For example, a study of 111 PD patients 
from Spain reported that 71.1% of patients did not have the usual dip in blood pressure as 
measured by 24-h ambulatory blood pressure monitoring (50).  
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Despite the consistently reported CRD among PD patients, it remains unclear whether these 
circadian changes result from dopaminergic treatment or PD disease progression itself. Earlier 
studies reported that the dopaminergic treatment might lead to phase advance of the melatonin 
rhythm(54, 55), while a more recent study among 29 PD patients (16 medicated and 13 non-
medicated) and 28 healthy controls from Australia found more than double the melatonin 
secretion and uncoupling of circadian and sleep-wake regulations in the treatment group (51). 
EDS is another potential consequence of dopaminergic treatment (47). One study in Norway 
suggested a doubled frequency of EDS among 153 drug-naive patients with early PD, compared 
to 169 age- and sex-matched controls at baseline, and a tripled frequency of EDS among these 
patients after 5 years of dopaminergic treatment compared to the controls (47). Larger studies 
with other circadian markers are needed to help clarify the effects of dopaminergic treatment on 
circadian rhythms, relative to neurodegeneration per se.   
 V. Disruption and risk of neurodegeneration  
A critical question is whether CRD is a cause or consequence of neurodegeneration, or both. If 
CRD were contributing to neurodegeneration, it would be expected to occur early in disease 
course (or precede disease), and would increase disease risk or rate of progression. While this 
question is still unanswered, growing evidence suggests that CRD might precede the 
development of clinical symptoms of neurodegenerative diseases. One recent study of 189 
cognitively normal older adults (50 with preclinical AD) reported that circadian rest-activity 
rhythm fragmentation appeared very early on in the preclinical phase of AD and correlated with 
AD-related pathology as assessed with PET imaging and cerebrospinal fluid (CSF) 
phosphorylated tau to amyloid β (Aβ)42 ratio (8). Several studies found a correlation between 
sleep-wake disturbances and increased levels of AD-related biomarkers or brain structural 
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change in cognitively normal older adults, though other biological markers of CRD were not 
specifically examined (10, 56, 57). Alterations in circadian melatonin rhythm were also found in 
healthy middle-aged men with worse cognitive trajectories in midlife (58). These cross-sectional 
findings suggested that CRD could be a result of preclinical AD pathology and may be a 
prodromal symptom or sign.  
Several longitudinal studies with long follow-up periods also reported greater cognitive decline, 
increased risk of all-cause dementia and increased risk of PD among those with circadian 
disturbances, including shift work (59-63). Table 3 shows longitudinal studies on CRD and risk 
of developing ADRD or PD published over the past five years. These studies all examined 
behavioral indicators of CRD, including actigraphy-measured rest-activity rhythm and daytime 
napping (9, 61, 64) and self-reported sleep timing(65). Two studies both found an association 
between lower circadian amplitude and greater cognitive decline over the next 3-5 years, in 
cognitively normal older men (64) and women (61) from the US. Bokenberger et al. reported in 
11,247 individuals from the Swedish Twin Registry that delayed rising time predicted dementia 
incidence over 17 years (65).  Another recent study of 2920 older men from the US suggested 
that those who napped for at least 1h per day were twice as likely to develop PD in 11 years (9). 
While all together these studies suggest that reduced circadian amplitude and circadian phase 
shifts precede the risk of ADRD, and that daytime inactivity precedes the risk of PD in healthy 
older adults, the number of published studies is small especially for PD. Additional confirmatory 
studies with long follow-up period are needed to determine whether CRD is a risk factor for 
ADRD and PD. Comprehensive and repeated measures of CRD with simultaneous assessment of 
preclinical disease biomarkers (such as amyloid and tau pathology) will also help understand the 
nature of this association.  
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VI. Underlying mechanisms  
a. Effects of neurodegenerative disease pathology on circadian clock function 
The mechanisms by which neurodegenerative pathology affects circadian function likely vary by 
specific disease.  In AD, human post-mortem neuropathological studies have demonstrated loss 
of critical neuronal populations in the SCN, including those expressing arginine vasopressin 
(AVP) or vasoactive intestinal peptide (VIP) (44, 66).  Both age- and AD-associated loss of VIP-
expressing neurons in the SCN were correlated with pre-mortem circadian dysfunction (Fig.1).  
However, the mechanisms driving SCN neuronal loss are unclear, as it is not a major site of 
amyloid plaque or neurofibrillary pathology.  Circadian abnormalities are observed in transgenic 
mouse models of AD, including those expressing human mutant amyloid precursor protein 
(APP), tau, or both.  However, there is great heterogeneity across mouse models, and little 
correlation with pathology, obscuring any definitive mechanistic conclusions (67-69).  Aβ 
peptide has been implicated as a mediator of circadian dysfunction, and in cultured cells it can 
induce degradation of the master clock protein BMAL1 (70, 71). However, this direct interaction 
between Aβ and the circadian clock has not been demonstrated in vivo in animals, or in humans. 
Altered methylation of the BMAL1 promoter, leading to altered BMAL1 expression and 
disrupted circadian rhythms, was described in fibroblasts from AD patients and in post-mortem 
AD brain samples, suggesting an underlying epigenetic mechanism of circadian disruption in AD 
(Fig.1) (45).  
b. Effects of circadian disruption on neurodegeneration 
There are several proposed mechanisms by which the circadian clock influences 
neurodegenerative disease (Fig. 1). Circadian dysfunction could promote neurodegeneration by 
altering sleep timing, leading to less consolidated nighttime sleep and increased daytime 
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napping.  Sleep deprivation causes altered Aβ dynamics in humans and increased Aβ and tau 
pathology in mouse models, and can increase inflammatory and neuronal injury markers in 
human cerebrospinal fluid (72-75). Sleep deprivation can also impact other aspects of 
neurodegeneration including protein clearance from the brain, inflammation, and synaptic 
homeostasis (76, 77). In this case, intervention to promote sleep should overcome any effect of 
circadian disruption. However, in mouse models, clock gene deletion in the brain can cause 
neuropathology without altering sleep, suggesting that sleep alone may not explain the brain 
effects of circadian disruption (78). 
Circadian regulation of immune responses may also contribute to the effects of circadian 
dysfunction on neurodegeneration.  The circadian system strongly modulates the peripheral 
immune response to inflammogens, as the degree of inflammation is highly dependent on time-
of-day of exposure (79, 80).  In a mouse experimental autoimmune encephalitis  model of 
neuroinflammation, the time of day of immunization has a striking impact on disease severity 
weeks later, while deletion of Bmal1 in myeloid cells exacerbates pathology (81, 82). In the 
brain, microglia and astrocytes represent the primary innate immune cells, and both cell types 
possess functional circadian clocks which regulate inflammatory activation (83, 84).  Deletion of 
Bmal1 in the brain, which disrupts all circadian clock function, causes widespread astrocyte 
activation and synaptic degeneration, emphasizing the importance of core clock function in 
maintaining innate immune homeostasis in the brain (78). In mouse models of Amyotrophic 
Lateral Sclerosis and PD, circadian disruption using non-24 hour light dark cycles led to 
increased glial activation and neuroinflammation and exacerbated neuropathology (85, 86).  
Thus, circadian dysfunction appears to promote aspects of neuorinflammation, which could 
influence neurodegeneration in many disease states. 
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The circadian clock could directly regulate protein homeostasis and quality control, thereby 
influencing protein aggregation in neurodegenerative diseases (87). In AD, levels of interstitial 
fluid Aβ peptide in the hippocampus show clear diurnal oscillation, which require an intact 
circadian system (88, 89).  Similar diurnal oscillations in Aβ are observed in human 
cerebrospinal fluid (90). Moreover, disruption of the circadian clock in a mouse β-amyloidosis 
model of AD leads to accelerated amyloid plaque deposition (89).  Circadian regulation in 
protein quality control systems, such as autophagy, may contribute to the circadian influence on 
protein aggregation in general (91, 92) .  Bulk removal of aggregated proteins from the brain by 
the glymphatic system, a glia-mediated perivascular fluid flow, has been associated with sleep, 
but its relation to the circadian system and the role of glial clocks in the process are still 
unclear(76).  Recent studies demonstrating circadian clock control of blood-brain barrier 
permeability may also have implications for protein aggregates clearance from the brain (93, 94). 
Finally, numerous studies reveal a complex, bidirectional relationship between the circadian 
clock and oxidative stress, a key pathogenic process in neurodegeneration (78, 95-98).  Thus, a 
number of potential identified mechanisms, as well as those which are not yet known, could link 
the circadian clock to neurodegenerative diseases.   
VII. Circadian Interventions 
If circadian dysfunction is a risk factor contributing to the development of neurodegenerative 
diseases, one of the appealing testable hypotheses is that enhancing circadian rhythms might 
prevent or halt the progress of these diseases as well as mitigating their related symptoms. 
Limited earlier studies have tested this hypothesis using timed light and/or melatonin treatments 
but provided inconsistent results (see Review by Forbes, et al.(99)). For instance, in a double-
blind, placebo-controlled, 2x2 factorial randomized trial of 189 residents of group care facilities 
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in the Netherlands (87% had dementia), Riemersma-van der Lek et al. examined the effects of 
daily treatment with whole-day bright of 1000 lux (as compared to dim light of 300 lux) and 
daily evening melatonin treatment (as compared to placebo) and found that the long-term light 
treatment (up to 3.5 years) attenuated cognitive decline with aging and improved depressive 
symptoms (100). However, Burn et al. did not find similar cognitive benefit of bright light in 
their randomized controlled trial of 48 patients in two nursing homes in the UK with diagnosed 
dementia, sleep disruption, and agitated behavior (101). The discrepancy may be attributed to 
uncontrolled treatment dose such as exposure duration and intensity of light that are especially 
important for the elderly with reduced response of the circadian system to light exposure (102); 
future studies should examine these possibilities. 
In the last five years, only two published circadian intervention studies examined patients with 
ADRD or PD. In a multicenter (one in the UK and four in the USA), double-blinded, parallel-
group study (103), sixty patients diagnosed with mild to moderate AD dementia (13 of them had 
insomnia) were randomized to receiving daily treatment of a prolonged-release melatonin 
formulation for 24 weeks or placebo. The study showed a positive effect of melatonin treatment 
on cognitive performance, especially for those with insomnia. The other study was performed in 
PD centers at Northwestern University and Rush University, where 31 patients with PD and 
coexistent excessive daytime sleepiness who received stable dopaminergic therapy underwent a 
14-day light intervention with twice 1-h exposure to bright or dim light each day (104). The light 
intervention improved daily activity rhythms and reduced daytime sleepiness, and the effects 
were stronger with bright light.  
The application of circadian interventions in neurodegenerative diseases is a promising but 
emerging field. Many questions and concerns remain to be addressed. (i) Circadian rhythms can 
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also be entrained or shifted by many other non-photic time cues or zeitgebers (105), including 
food (106), caffeine consumption (107) and exercise (108). These zeitgebers affect circadian 
rhythms likely through direct influences on the peripheral clocks and their feedback to the central 
circadian clock (109). How to appropriately implement these time cues in circadian interventions 
requires better understanding of the interactions between the central and peripheral clocks. (ii) 
The intrinsic properties such as the period of the central circadian clock can be different between 
individuals, leading to different chronotypes (i.e., evening- and morning-types) and different 
circadian timings (relative to time of day) of behavior and physiological functions including 
melatonin secretion. Thus, individuals of different chronotypes have different responses even 
when light exposure and melatonin are scheduled at the same time of day (110). However, no 
clinical trials have incorporated chronotype into personalized circadian interventions. (iii) 
Though circadian control and sleep regulation are tightly coupled, they have different underlying 
mechanisms. Understanding these specific mechanistic pathways in addition to distinguishing 
whether the observed beneficial effects of interventions are through the influences on the 
circadian clocks or directly on the neural circuitry of sleep homeostasis may improve strategies 
for future drug and therapeutic design. (iv) Despite the association between circadian 
disturbances and cognitive impairment, more evidence for the impacts of circadian interventions 
on cognitive decline and the progression of neurodegenerations over a long term (e.g., >5 years), 
especially after the intervention period, is required. (v) No circadian intervention study has 
considered neuropathological biomarkers. Using structural MRI or PET scans of the brain and 
examining longitudinal changes in CSF Aβ and tau levels will help clarify the contributions of 
circadian disturbances to neuropathological and anatomical changes in the brain, which may 
provide insights into potential mechanisms. (vi) Previous studies have been exclusively focused 
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on the stages of neurodegenerative diseases after the clinical onset of the diseases. It will be 
important to test the benefits of circadian therapies for the prevention of the diseases and related 
symptoms at preclinical stages.  
VIII. Conclusions and future directions 
People with ADRD or PD frequently experience disruptions in both behavioral and biological 
markers of CRD, including disrupted sleep-wake cycles, impaired hormonal and body 
temperature rhythms, dysregulated autonomic system as well as fluctuated neuropsychiatric 
symptoms. CRD in neurodegeneration is often presented in a much more severe form than 
typical age-related CRD and also has distinct features. Unlike healthy older adults who usually 
have reduced circadian amplitude and advanced circadian phase, patients with ADRD tend to 
have high fragmentation and slightly reduced amplitude of circadian rhythms. There are mixed 
findings regarding phase shift among these patients, and they are likely to have irregular sleep-
wake patterns. PD patients tend to have reduced circadian amplitude but no change in circadian 
phases. In general, behavioral CRD markers have been examined more than biological markers. 
Recent evidence has also suggested that the stage and severity of the disease, as well as the 
treatment, increase variation in markers of CRD. Larger longitudinal clinical studies are needed 
to examine the change in circadian rhythms with the progression of neurodegeneration, including 
non-AD dementias, and to disentangle the effects of PD progression and dopaminergic treatment 
on circadian rhythms. The integration of non-behavioral circadian biomarkers into these studies 
would help disentangle CRD from sleep/behavioral confounds (see Directions for future 
research). This will help identify circadian features that are important for differentiating various 
types and stages of neurodegenerative diseases, and is important for the management of circadian 
symptoms in these diseases.  
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Several epidemiologic studies suggested the presence of circadian disturbances at the preclinical 
stage of ADRD. CRD might be considered as a useful preclinical marker or prodromal for 
neurodegenerative diseases and help with the early detection of the disease. Emerging evidence 
from longitudinal studies also showed that CRD precedes the development of ADRD or PD. 
Additional confirmatory studies with longer follow-up are needed to examine the relationship 
between different circadian markers and subsequent risk of developing neurodegenerative 
diseases, and should consider the use of biomarkers to help understand potential mechanisms. 
For example, using structural MRI or PET scans of the brain and examining longitudinal changes 
in CSF Aβ and tau levels will help clarify if circadian disturbances might contribute to AD 
pathology or structural change in the brain. Studies of biological mechanisms and intervention 
trials are required to determine if CRD is a cause of neurodegenerative diseases.  
Finally, personalized multicomponent circadian intervention should be developed and tested for 
its benefits on circadian synchronization as well as symptom management of ADRD or PD. In 
addition, larger longitudinal clinical trials with longer follow-up are also needed to examine the 
long-term benefits of these interventions, and especially to determine whether these interventions 
might help prevent or delay the onset of neurodegenerative diseases among healthy older adults, 
or delay symptoms in those at the preclinical stage. In this way, CRD may be a promising 
therapeutic target for the prevention and management of neurodegenerative diseases.         
VIIII. Search strategy and selection criteria 
We identified references for this Review by searches of PubMed between Jan 2013 and Oct 
2018, and by hand searches of reference lists from relevant articles. We used the search terms: 
“dementia”, “Alzheimer’s disease”, “cognitive function”, “cognitive decline”, “cognition”, 
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“Parkinson disease”, “neurodegeneration” and "circadian rhythm", “circadian clock”, “twenty-
four-hour rhythm”, “sleep-wake”, “melatonin” or “chronotherapy”.  There were no language 
restrictions. We included only references published within the past 5 years, except for key or 
landmark studies in the field. The final reference list was made based on relevance to the theme 
of this review.    
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Panel 2.  
  
Directions for future research 
 Studies of CRD in neurodegeneration should incorporate the assessment of both biological and 
behavioral markers of CRD. 
 Larger, longitudinal studies are needed to determine circadian features for different types and 
severities of ADRD, and clarify the link between the progression of ADRD and change in 
circadian rhythm disruptions.  
 The interaction between PD disease progression, dopaminergic treatment and circadian changes 
should be clarified. 
 Additional studies with long follow-up period are needed to confirm the effects of CRD on 
subsequent cognitive decline and risk of developing ADRD or PD.  
 Establishment of underlying mechanisms for the bi-directional relationship between circadian 
rhythms and neurodegeneration are needed to help draw causal inference and inform 
therapeutic targets.   
 The use of circadian interventions in patients with neurodegenerative diseases should be further 
explored, and personalized circadian treatment should be considered given the large between-
individual differences. 
 Randomized controlled trials of individuals at preclinical stages are needed to test the benefits 
of circadian therapies for the prevention of neurodegenerative diseases and related symptoms.  
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 Table 1. Case-control studies of circadian rhythm disruptions among patients with dementia (2013-2018)
First author, 
year 
Sample Type of circadian 
markers   
Measure of 
circadian markers 
Results 
Musiek, 
2018(8) 
189 cognitively normal older 
adults (mean age 67y, 50 with 
preclinical amyloid pathology and 
139 amyloid negative) 
Rest-activity 
rhythm 
7 to 14-day 
actigraphy 
Those with preclinical AD had increased rest-activity 
rhythm fragmentation (p=0.008) but no significant 
difference in the amplitude or phase, after adjusting 
for age and sex.  
Weissova, 
2016(3) 
13 mild AD patients and 13 age-
matched controls (mean age 78y) 
Rest-activity 
rhythm; melatonin 
rhythm; peripheral 
clock gene 
expression   
21-day actigraphy; 
sleep diary; saliva 
melatonin assay; real-
time polymerase 
chain reaction 
There was a significantly higher number of daytime 
naps among AD patients (1.76 ± 0.61) than among 
controls (0.17 ± 0.05); AD patients had dampened 
melatonin profiles and slightly reduced amplitude of 
melatonin rhythm; There was no significant difference 
in PER1 and BMAL1 expression. 
La Morgia, 
2016(42) 
16 mild-moderate AD patients 
and 10 age-matched controls 
(mean age 68y) 
Rest-activity 
rhythm 
7-day actigraphy  AD patients had a slightly reduced rhythm amplitude 
(p=0.04), were less active during the wake period but 
more active during the night; there were large 
individual variabilities among AD patients.  
Wang, 
2015(44) 
7 AD patients and 10 age-
matched controls (mean age 90y 
at death) 
Rest-activity 
rhythm 
≥7-day actigraphy 
within the 18 months 
prior to death 
AD patients had a significant phase delay (activity 
nadirs and acrophases occurred 2.9 hours later than in 
controls); there was no significant difference in 
rhythm amplitude.  
Hooghiemstra, 
2015(4) 
61 patients with EOD and 67 
controls (mean age 62y) 
Rest-activity 
rhythm 
7-day actigraphy Patients with EOD had increased rest-activity rhythm 
fragmentation (p=0.03) but no significant difference in 
the amplitude or regularity.  
Liguori, 
2014(43) 
48 drug-naïve AD patients (21 
mild and 27 moderate to severe) 
and 29 controls (mean age 71y) 
Sleep timing Polysomnography Those who had AD, especially moderate to severe AD 
had earlier bedtimes (10:15pm and 9:45pm, 
respectively), compared to controls (11:30pm) and 
those with mild AD (10:45); there was no difference 
in rise times. 
Naismith, 
2014(40) 
26 MCI patients and 26 age-
matched controls (mean age 68y) 
Sleep timing; 
melatonin rhythm 
14-day actigraphy; 
saliva melatonin 
assay 
MCI patients had earlier melatonin and sleep onset 
compared to controls; there was no significant 
difference in melatonin levels. 
Ortiz-Tudela, 
2014(41) 
21 MCI patients and 19 age-
matched controls (mean age 73y)  
Rest-activity 
rhythm; 
temperature rhythm 
7-day actimeter; wrist 
temperature sensor 
MCI patients showed a significant phase advance in 
both temperature and activity rhythm. 
AD: Alzheimer’s disease; EOD: Early-onset dementia; MCI: mild cognitive impairment 
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Table 2. Case-control studies of circadian rhythm disruptions among patients with Parkinson’s disease (2013-2018)  
  
First author, 
year 
Sample Type of circadian 
markers   
Measure of 
circadian markers 
Results 
Tholfsen, 
2015 (47) 
153 drug-naive PD patients and 
169 age- and sex-matched 
controls (mean age 66y) 
EDS ESS 11.8% PD patients and 4.7% controls had EDS at 
baseline; after 5 years on PD medication, 23.4% 
PD patients and 8% controls had EDS. 
Videnovic, 
2014 (5) 
20 PD patients and 15 age-
matched controls (mean age 64y) 
Melatonin rhythm; 
EDS 
Plasma melatonin 
by 24-h repeated 
blood sampling; 
ESS 
60% PD patients and 27% controls had EDS 
(p<0.01); PD patients also had reduced melatonin 
rhythm amplitude (p<0.001) and 4-fold decrease 
in 24-h AUC for circulating melatonin levels; 
there was no significant difference in DLMO.  
Breen,  
2014 (48) 
30 PD patients and 15 age- and 
sex-matched controls (mean age 
at diagnosis 68y) 
Sleep timing; EDS; 
melatonin rhythm; 
cortisol rhythm; 
peripheral clock 
gene expression 
14-day actigraphy; 
ESS; serum 
melatonin and 
cortisol by 24-h 
repeated blood 
sampling  
PD patients had more fragmented motor activity 
during 24-h (p=0.01) and later sleep onset time 
(p=0.04); they had reduced circulating melatonin 
levels (p=0.05), increased cortisol levels 
(p<0.001) and altered Bmal1 expression 
(p=0.04); there was no difference in the timing of 
melatonin or cortisol onset or offset.  
Bolitho,  
2014 (51) 
29 PD patients (16 medicated and 
13 non-medicated) and 28 age-
matched controls (mean age 66y) 
Sleep timing; 
melatonin rhythm; 
phase angle of 
entrainment  
14-day actigraphy 
and saliva melatonin 
assay 
There were no differences in sleep timing or 
DLMO; dopaminergic treatment more than 
doubled the melatonin secretion and the phase 
angle of entrainment. 
Zhong,  
2013 (49) 
12 PD patients and 11 age-
matched controls (mean age 64y) 
Sleep timing; core-
body temperature 
profiling 
14-day actigraphy; 
temperature profile 
recorded by 24-h 
ingestible capsule 
sensor 
PD patients had lower temperature mesor 
(p=0.02) and reduced nocturnal temperature 
amplitude (p=0.04); there was no significant 
difference in sleep timing.   
Berganzo, 
2013 (50) 
111 PD patients (mean age 68y) Blood pressure 24-h ambulatory 
blood pressure 
monitoring 
71.1% of PD patients had no proper 
physiological circadian rhythm; PD patients had 
a great burden of nocturnal hypertension. 
AUC: Area under the curve; DLMO: Dim light melatonin onset; EDS: Excessive Daytime Sleepiness; ESS: Epworth Sleepiness Scale; PD: 
Parkinson’s disease. 
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Table 3. Longitudinal studies on circadian disturbances and subsequent risk of neurodegenerative diseases (2013-2018) 
 
 
 
First author, 
year 
Sample Length of 
follow-up 
Type& measure 
of Circadian 
measure 
Outcome measure Results 
Cognitive impairment including ADRD   
Rogers-
Soeder,2018 (64) 
2754 men 
(mean age 
76y) 
3.4y Actigraphy 
measured rest-
activity rhythm 
Cognitive decline by 
tests of global 
cognition and 
executive function 
Lower circadian amplitude and 
phase advance was associated with 
greater cognitive decline. 
Bokenberger, 
2017(65) 
11,247 
adults (mean 
age 73y)  
17y Sleep timing 
measured by 
Karolinska Sleep 
Questionnaire 
Incident dementia by 
ICD-10 codes 
Delayed rising time was 
associated with increased 
dementia risk. 
Walsh, 2014 (61) 1287 
women 
(mean age 
83y) 
5y Actigraphy 
measured circadian 
activity rhythm 
variables  
Cognitive decline by 
tests of global 
cognition, memory 
and executive 
function 
Lower circadian amplitude was 
associated with worse cognitive 
function, especially executive 
function. 
Parkinson’s disease     
Leng, 2018 (9) 2920 men 
(mean age 
76y) 
11y 
 
Actigraphy 
measured daytime 
napping 
Incident PD defined 
by self-report or PD 
medication use 
Long daytime napping was 
associated with increased risk of 
PD. 
AD: Alzheimer’s disease; MCI: Mild Cognitive Impairment; PD: Parkinson’s disease.  
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Figure 1. Hypothesized bi-directional relationship between CRD and neurodegeneration.  The central circadian clock influences 
sleep timing, which directly controls Aβ dynamics (in humans and mice) and glymphatic clearance of toxic proteins (in animals).  
Sleep disruption also alters a host of other factors, from synaptic homeostasis to inflammation. Circadian clocks in microglia and 
astrocytes may regulate the blood/brain barrier (BBB), inflammation, and synaptic function, though this is speculative. Animal studies 
suggest that circadian clocks in neurons influence brain oxidative stress, and could affect brain metabolic function and synaptic 
homeostasis.  Finally, peripheral clocks in organs such as the gut and liver impact peripheral metabolism, the microbiome, and 
immune function. In total, this multi-system perturbation could promote toxic protein aggregation and neurodegeneration, which in 
turn could disrupt circadian clocks in the SCN and periphery. Black arrows=supported by human data, Blue arrows=supported by 
animal data, Grey arrows=speculative. 
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